Treatment of Latent Tuberculosis Infection Based on the Interferon-γ Release Assay in Allogeneic Stem Cell Transplant Recipients
Joung Ha Park, Eun‐Ji Choi, Han‐Seung Park, Sang‐Ho Choi, Sang‐Oh Lee, Yang Soo Kim, Jun Hee Woo, Jung‐Hee Lee, et al. (12 authors)
Clinical Infectious Diseases · 2020-01
Abstract
In hematopoietic stem cell transplant recipients, the incidence of tuberculosis in positive interferon-γ release assay (IGRA) without isoniazid prophylaxis (3.58/100 person-years) was higher than in negative or indeterminate IGRA (1.15/100 person-years; P = .01) and in positive IGRA with isoniazid prophylaxis (0/100 person-years; P = .09). The number needed to treat was 22 (95% confidence interval, 12-99) with positive IGRA results.
MeSH terms
- Latent tuberculosis
- Medicine
- Isoniazid
- Stem cell
- Tuberculosis
- Immunology
- Internal medicine
- Incidence (geometry)
- Confidence interval
- Hematopoietic stem cell transplantation
- Transplantation